A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer

Recruiting

Phase 2

PCS6422 with CapecitabineA Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer

Sponsor:

Processa Pharmaceuticals

Code:

NCT06568692

Conditions

Breast Cancer

TNBC - Triple-Negative Breast Cancer

HER2-negative Breast Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

PCS6422 and capecitabine

Capecitabine

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-27. This information was provided to ClinicalTrials.gov by Processa Pharmaceuticals on 2025-03-25.